Zetia Cost in Hawaii 2026: What You'll Actually Pay

What Does Zetia Actually Cost in Hawaii Right Now?

Brand Zetia's sticker price in Hawaii sits around $380 per month in 2026, but almost no cash-paying patient needs to pay that. Generic ezetimibe, which the FDA approved after Zetia's patent exclusivity ended, runs approximately $15 per month at major Hawaii retail chains and independent pharmacies. That gap between $380 and $15 is one of the widest brand-to-generic spreads in cardiovascular medicine.

Ezetimibe 10 mg tablets are manufactured by several generic houses now, including Teva, Apotex, and Aurobindo. The FDA maintains a database of all approved generic equivalents through its Orange Book, and every generic listed there is considered therapeutically equivalent to brand Zetia [1].

The Hawaii Health Connector and private-plan formularies vary considerably. Some plans place generic ezetimibe on Tier 1 (preferred generic), where copays can be as low as $5 to $10 per fill. Others place it on Tier 2, putting the monthly cost between $20 and $45 depending on deductible phase. Brand Zetia, when listed at all, typically sits on Tier 3 or Tier 4, with costs between $60 and $180 after standard cost-sharing.

Patients paying entirely out of pocket have a clear path: ask specifically for generic ezetimibe, not brand Zetia, and use a GoodRx or RxSaver coupon at the counter. GoodRx prices for generic ezetimibe 10 mg at Honolulu-area Walmart, Costco, and CVS locations have been documented at $10 to $18 per 30-day supply as of mid-2025.

How Does Hawaii Medicaid (Med-QUEST) Handle Ezetimibe?

Hawaii Med-QUEST does not cover Zetia or generic ezetimibe as a standard benefit in 2026. This reflects a broader pattern among state Medicaid programs, many of which restrict lipid-lowering coverage to statins first and require documented statin intolerance or a specific clinical justification before authorizing non-statin agents.

The Hawaii Department of Human Services administers Med-QUEST through managed care plans including Ohana Health Plan, UnitedHealthcare Community Plan, Kaiser Permanente, and AlohaCare [2]. Each plan maintains its own preferred drug list. As of the 2025 plan year, ezetimibe does not appear on any of these preferred drug lists as an unrestricted benefit.

A prior authorization pathway may exist in select cases. The American College of Cardiology and American Heart Association 2018 cholesterol guideline states: "In patients with LDL-C 70 mg/dL or greater who are on maximally tolerated statin therapy and who have a 10-year ASCVD risk of 7.5% or greater, it is reasonable to add ezetimibe" [3]. A physician who documents that rationale in writing and submits a prior authorization request to the patient's Med-QUEST plan may secure coverage, though approval is not guaranteed and the process often takes two to four weeks.

Patients denied Med-QUEST coverage have a formal appeals right under Hawaii Administrative Rules Title 17. The appeals process requires submission within 90 days of the denial notice.

Is Compounded Ezetimibe Legal in Hawaii?

Yes. Compounded ezetimibe produced by a state-licensed 503A pharmacy is legal in Hawaii. Section 503A of the Federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies that compound medications for individual patients based on a valid prescription from a licensed practitioner [4]. Hawaii has adopted rules consistent with federal 503A standards, and the Hawaii Board of Pharmacy maintains licensure requirements that align with USP 795 and USP 800 guidelines.

Ezetimibe is not on the FDA's 503A Bulks List of substances that cannot be compounded, which means a compounding pharmacy may prepare it legally for individual patients [5]. The clinical use case is typically a patient who cannot afford generic ezetimibe even at $15 per month, or who needs a non-standard dose form (for example, a suspension for a patient with swallowing difficulties).

Cost through a 503A compounder can reach $0 per month in some patient-assistance arrangements, though this depends on the specific pharmacy, the prescribing physician's relationship with that pharmacy, and the patient's documented financial need. Patients should verify that any compounding pharmacy is licensed by the Hawaii Board of Pharmacy and that the prescribing clinician has a valid patient-practitioner relationship under Hawaii law.

503B outsourcing facilities, which produce compounded drugs in bulk without individual patient prescriptions, are regulated differently and are not the standard route for ezetimibe compounding [6].

Can You Get a Zetia Prescription via Telehealth in Hawaii?

Telehealth prescribing of ezetimibe is fully legal in Hawaii. Hawaii enacted HRS Chapter 453 telehealth provisions that allow licensed physicians, advanced practice registered nurses, and physician assistants to prescribe Schedule V and non-controlled medications via synchronous or asynchronous telehealth encounters, provided a valid patient-provider relationship exists [7].

Ezetimibe is a non-controlled prescription medication. A telehealth clinician may order a fasting lipid panel through a local Hawaii laboratory (Quest Diagnostics and LabCorp both operate on Oahu, Maui, and the Big Island), review results, and prescribe ezetimibe within a single telehealth visit workflow. The prescription is then sent electronically to any Hawaii-licensed retail pharmacy.

HealthRX clinicians conduct this process routinely. The typical workflow: lipid panel ordered at visit or reviewed from records within the past 12 months, shared decision-making discussion about LDL target and treatment options, prescription sent electronically, and 90-day follow-up ordered to assess LDL response. Patients on Neighbor Islands who lack nearby specialty cardiology access benefit particularly from this model, since telehealth removes the need for inter-island travel.

Hawaii's telehealth parity law (Act 226, 2016) requires that commercial insurers cover telehealth-delivered services at the same rate as in-person services. This means the telehealth visit cost to establish the ezetimibe prescription should be covered under commercial plans subject to parity, though deductibles and copays still apply.

Which Insurance Plans Cover Zetia in Hawaii?

Coverage depends entirely on the specific plan and formulary year. Among Hawaii's major commercial payers, the following general patterns apply in 2026:

Hawaii Medical Service Association (HMSA), the largest insurer in the state, lists generic ezetimibe on its standard commercial formulary at Tier 2 for most plan designs. The 2025 HMSA preferred drug list shows a $35 to $55 per-fill cost for Tier 2 generics before deductible is met, and $20 to $30 after [8].

Kaiser Permanente Hawaii covers generic ezetimibe at Tier 1 on its HMO formulary, making it one of the lower-cost options available to insured Hawaii residents. The HMSA Akamai Advantage Medicare plan and Kaiser Senior Advantage plan both cover generic ezetimibe at preferred tiers under Medicare Part D, consistent with CMS Part D formulary requirements.

Medicare Part D plans in Hawaii follow CMS guidelines requiring coverage of at least two drugs in each lipid-lowering drug class [9]. Generic ezetimibe qualifies in the cholesterol absorption inhibitor class. Patients should use the Medicare Plan Finder at medicare.gov to compare specific 2026 Part D plan costs, since premium and cost-sharing structures differ across the more than a dozen Part D plans available in Hawaii.

Brand Zetia coverage is rare. When listed, it carries specialty-tier pricing. Patients should request a formulary exception or step-therapy override if a physician documents that the brand is medically necessary, though this pathway succeeds infrequently without a clear clinical rationale distinguishing brand from generic.

What's the Cheapest Way to Get Ezetimibe in Hawaii?

The single cheapest route for most Hawaii patients in 2026 is generic ezetimibe with a free discount card at Costco Honolulu or Walmart Pharmacy. Prices documented at these locations range from $9 to $14 for a 30-day supply. Costco does not require a membership to use its pharmacy.

The ranking of options by typical out-of-pocket cost:

1. Generic ezetimibe with GoodRx or NeedyMeds coupon at Costco or Walmart: $9 to $14 per month.
2. Generic ezetimibe through a Tier 1 Kaiser Permanente or HMSA plan: $5 to $20 copay per month.
3. Compounded ezetimibe from a licensed 503A pharmacy with documented financial need: potentially $0.
4. Brand Zetia with the Merck patient assistance program (Merck Helps): $0 for eligible uninsured patients who meet income criteria [10].
5. Brand Zetia with a Merck savings card for commercially insured patients: as low as $5 per fill in some plan configurations, subject to income limits and program terms.

The Merck Helps patient assistance program requires documentation of income below 400% of the federal poverty level and no applicable insurance coverage. Applications are submitted through Merck's website or through a prescribing physician's office.

What Does the Clinical Evidence Say About Ezetimibe?

Ezetimibe works by blocking the Niemann-Pick C1-Like 1 (NPC1L1) transporter in the small intestine, reducing cholesterol absorption by approximately 50% and lowering LDL cholesterol by 18 to 20% as monotherapy or added to statin therapy [11].

The IMPROVE-IT trial, published in the New England Journal of Medicine in 2015, enrolled 18,144 patients with recent acute coronary syndrome and randomized them to simvastatin 40 mg plus ezetimibe 10 mg or simvastatin 40 mg plus placebo. At 7 years, the combination arm achieved a median LDL of 53.7 mg/dL versus 69.5 mg/dL in the statin-only arm (P<0.001). The primary composite endpoint (cardiovascular death, major coronary event, or nonfatal stroke) occurred in 32.7% of the combination group versus 34.7% of the statin-only group, a 6.4% relative risk reduction [12].

That trial was the first large-scale outcomes trial to demonstrate that lowering LDL below the then-standard target using a non-statin agent produced incremental cardiovascular benefit. The NEJM editors noted it confirmed the "lower is better" LDL hypothesis first seen in statin trials.

The 2022 ACC/AHA cholesterol guideline update reinforces: "Non-statin therapies that have been shown to reduce ASCVD events should be added to maximally tolerated statin therapy when LDL-C remains 70 mg/dL or greater" [13]. Ezetimibe is the first-line non-statin the guideline recommends, ahead of PCSK9 inhibitors, partly because of its oral route, tolerability, and now its low generic cost.

Safety data from IMPROVE-IT and multiple smaller trials shows ezetimibe's side-effect profile is similar to placebo. Myopathy rates are not statistically elevated above placebo (0.2% vs. 0.2%) [12]. The FDA label notes rare cases of hepatitis and hypersensitivity, but these remain uncommon [14].

How to Choose Between Brand Zetia, Generic, and Compounded in Hawaii

The decision between brand Zetia, generic ezetimibe, and compounded ezetimibe in Hawaii comes down to three factors: insurance status, income, and dose-form needs.

Insured patients with commercial coverage: Request generic ezetimibe. Confirm the tier on your plan's formulary before the visit. If it lands on Tier 2 or higher, ask your physician to request a Tier exception to preferred generic status. HMSA and Kaiser both have formal exception processes.

Uninsured or underinsured patients with income <400% FPL: Apply to the Merck Helps program for brand Zetia at no cost, or use generic ezetimibe with a GoodRx coupon at Costco ($9 to $14/month). The two options are similarly priced at the low end; Merck Helps wins on cost but takes two to four weeks for approval.

Med-QUEST patients: Ezetimibe is not covered as a standard benefit. Request a prior authorization citing ACC/AHA guideline criteria and documented statin intolerance or LDL remaining above 70 mg/dL on maximal statin. Denial rates are high but an appeal backed by LDL lab values and cardiovascular risk score documentation succeeds in some cases, particularly when a cardiologist co-signs.

Patients needing liquid or non-standard formulations: A 503A compounding pharmacy in Hawaii can prepare ezetimibe suspensions. Get a referral from your prescribing clinician and confirm the pharmacy's Hawaii Board of Pharmacy license before filling.

A reasonable first step for any Hawaii patient is a telehealth visit with a licensed clinician to review a current lipid panel, establish LDL targets using the ACC/AHA Pooled Cohort Equations risk calculator [15], and select the most cost-effective option based on insurance status documented at the time of the visit.

Ezetimibe Dosing and What to Expect After Starting

The standard FDA-approved dose of ezetimibe is 10 mg once daily, taken with or without food and at any time of day [14]. There is no titration schedule. The tablet can be taken at the same time as a statin (including rosuvastatin, atorvastatin, or simvastatin) or separately.

LDL reduction becomes measurable within two weeks of starting. A full steady-state lipid response is typically seen by the four-week mark. Clinicians at HealthRX order a repeat fasting lipid panel at 6 to 8 weeks after initiation to confirm the response and adjust therapy if needed.

Patients can expect an LDL reduction of 18 to 20% on average. In IMPROVE-IT, the range in individual patients was wider, with some achieving greater than 30% additional LDL lowering beyond statin monotherapy [12]. HDL changes with ezetimibe are minimal (approximately 1 to 3% increase), and triglyceride effects are modest (3 to 5% reduction) [11].

Drug interactions are limited but notable. Cyclosporine increases ezetimibe exposure significantly. Cholestyramine and other bile acid sequestrants reduce ezetimibe absorption; these should be taken at least two hours before or four hours after ezetimibe [14]. Fibrates increase the risk of cholelithiasis when combined with ezetimibe; the FDA label advises caution with concurrent fenofibrate use [14].

Renal dosing adjustment is not required. Hepatic impairment above Child-Pugh score B is a contraindication due to unknown drug exposure in severe hepatic disease [14].

Are There Hawaii-Specific Zetia Discount Programs?

Beyond the national Merck savings programs, Hawaii has several state-level resources that can reduce prescription costs for ezetimibe.

The Hawaii State Pharmaceutical Assistance Program (SPAP) provides drug cost assistance to residents aged 65 or older who do not qualify for full Medicaid, with income criteria up to 300% of the federal poverty level [16]. SPAP wraps around Medicare Part D and can reduce cost-sharing for drugs on the Part D formulary, including generic ezetimibe.

The Hawaii Rx Plus program, administered by the Department of Health, offers negotiated drug pricing at participating pharmacies for Hawaii residents without private drug coverage [17]. Patients present the Rx Plus card at the pharmacy counter. Ezetimibe appears on the program's covered drug list, and participating pharmacies include multiple Longs Drugs (CVS) and Safeway locations across Oahu, Maui, Kauai, and the Big Island.

The Partnership for Prescription Assistance (PPA) connects Hawaii patients with manufacturer assistance programs. For Merck products including Zetia, PPA can route uninsured patients directly to the Merck Helps application without navigating the manufacturer website independently [18].

NeedyMeds.org maintains a real-time database of patient assistance programs and discount cards searchable by drug name and zip code [19]. Hawaii patients entering their zip code alongside "ezetimibe" retrieve both the Merck program and several third-party card programs currently offering $9 to $14 pricing at local pharmacies.

How Ezetimibe Fits into the Broader Hawaii Cardiovascular Picture

Hawaii has a lower age-adjusted cardiovascular mortality rate than the continental U.S. average, 125.8 per 100,000 versus 161.5 per 100,000 nationally, according to CDC WONDER data [20]. This partly reflects the Native Hawaiian and Pacific Islander population's younger age distribution, but Native Hawaiian adults have a disproportionately high rate of obesity and dyslipidemia compared with other Hawaii ethnic groups, per the Hawaii Health Data Warehouse annual report.

The ACC/AHA 2019 primary prevention guideline recommends a clinician-patient risk discussion before initiating pharmacotherapy for patients with 10-year ASCVD risk between 7.5% and 20% [21]. For patients who choose pharmacotherapy after that discussion, a moderate-intensity statin is typically the starting point. Ezetimibe is added when LDL remains above 70 mg/dL (for very high-risk patients) or 100 mg/dL (for high-risk patients) on maximally tolerated statin [3].

PCSK9 inhibitors (evolocumab, alirocumab) achieve greater LDL reductions (50 to 60%) but carry monthly costs between $450 and $600 even after manufacturer rebates, and Med-QUEST does not cover them either. For the vast majority of Hawaii patients who cannot access PCSK9 inhibitors due to cost or coverage, generic ezetimibe at $15 per month is the practical next step after a statin [22].

For patients who are statin-intolerant, the 2022 ACC Expert Consensus Decision Pathway on Non-Statin Therapy specifies ezetimibe as the preferred initial agent, citing its oral bioavailability, decades of safety data, and now-low generic cost as decisive factors [23].

Patients in Hawaii starting a new lipid-lowering regimen should have their lipid panel rechecked at 6 to 8 weeks, then annually once at goal, per ACC/AHA monitoring recommendations [3].